OCT4, Ki-67 and VEGF as Prognostic Factors in Endometrial Carcinoma and Their Role in The Differentiation between Atypical Endometrial Hyperplasia and Grade 1 Endometrial Carcinoma: an Immunohistochemical study

Noha M. El -Anwar and Alaa I. Amer
Welcome letter from Editor-in-Chief

Welcome to the Int J Cancer and Biomedical Research (IJCBR)!

It is with great pleasure that I write this editorial to welcome you to the IJCBR. This journal provides a platform for publication of original and reviews research articles, short communications, letter to editor, thesis abstract, conference report, and case studies. These types of publication are directed at the interface of the fields of cancer and biomedical research.

The IJCBR relies on a distinguished expert of the Advisory and Editorial Board Members from the top international league covering in depth the related topics. They timely review all manuscripts and maintain highest standards of quality and scientific methodology and ethical concepts. Meanwhile, we take all possible means to keep the time of the publication process as short as possible.

I take this chance to welcome your contributions to the IJCBR and have every expectation that it will soon become one of the most respected journals in both the fields of cancer and biomedical research.

Mohamed L. Salem,

Editor in Chief
OCT4, Ki-67 and VEGF as Prognostic Factors in Endometrial Carcinoma and Their Role in The Differentiation between Atypical Endometrial Hyperplasia and Grade 1 Endometrial Carcinoma: an Immunohistochemical study

Noha M. El-Anwar¹,² and Alaa I. Amer¹

¹Pathology Department, Faculty of Medicine, Tanta University, Egypt
²Pathology Department, Armed Forces College of Medicine, Egypt

ABSTRACT

Background: Endometrial carcinoma develops through preliminary stages of endometrial hyperplasia. A population of epithelial stem cells was identified in the human endometrium, these cells may serve as a source of putative endometrial carcinoma. The most important member of cancer stem cell markers is OCT-4. Both tumor cell proliferation (Ki-67) and angiogenesis seem to be important for the development of aggressive tumors. Aim of the Work: This study aimed to evaluate the expression of OCT4, Ki-67 and VEGF in endometrial hyperplasia and endometrial carcinoma and to differentiate between grade 1 endometrial carcinoma and atypical endometrial hyperplasia. Materials and Methods: 60 cases of endometrial hyperplasia and 60 cases of endometrial carcinoma were stained by OCT4, Ki-67 and VEGF immunohistochemical markers. Results: OCT-4 expression was significantly increased with advanced tumor grade and stage (P value = 0.001, 0.044) respectively. There was also significant association between Ki-67 expression and advanced tumor grade and stage (P value = 0.0016, 0.049) respectively. VEGF expression was significantly increased with advanced tumor grade and stage (P value = 0.001) for both. As regards the correlation of immunohistochemical results between atypical endometrial hyperplasia versus grade 1 endometrial carcinoma cases, Ki-67 was the marker with significant relation. Conclusion: OCT-4, Ki-67 and VEGF expressions showed a positive correlation with tumor aggressive pathological parameters. The Ki-67 labelling index can be used in differentiation between endometrial hyperplasia with atypia and grade 1 endometrial carcinoma.

Keywords: Endometrial, Carcinoma, Hyperplasia, Ki-67, OCT4, VEGF

INTRODUCTION

Worldwide, endometrial carcinoma is the sixth most common malignant tumor in women. It develops through preliminary stages of endometrial hyperplasia. Accurate diagnosis and optimal treatment of endometrial hyperplastic lesions are essential to prevent endometrial carcinoma development (Malpica et al., 2019).

It may be difficult, or sometimes even impossible, in a small biopsy specimen to distinguish between atypical endometrial hyperplasia and a grade 1 endometrial carcinoma as these two lesions don’t have clearly defined boundaries. In patients with a diagnosis of atypical endometrial hyperplasia on an endometrial biopsy, there is a significant risk of finding a grade 1 endometrial carcinoma in a subsequent hysterectomy specimen (Yang et al., 2020).

Several histological features help to distinguish between atypical endometrial hyperplasia and grade 1 endometrial carcinoma. The desmoplastic stromal response, back-to-back glandular architecture with complete exclusion of stroma and bridging between adjacent glands...
resulting in cribriform pattern and papillary architecture are in keeping with carcinoma. The differentiation between these two entities is important for surgical management or conservative treatment for patients wishing to preserve their childbearing potential (Murali et al., 2014).

A population of epithelial stem cells was identified recently in the human endometrium. The endometrial stem cell (ESC) associated proteins may contribute to tumorigenesis. OCT-4 is transcription factors that form a core regulatory network that determines endometrial stem cell (ESC) self-renewal and differentiation. In support of this hypothesis, clinical studies have shown that elevated expression of OCT-4 is associated with different tumors e.g. retinoblastoma, prostate cancer, metastatic germ cell tumors, and ovarian cancer (Lu et al., 2020).

The Ki-67 protein is a cellular marker for proliferation. Ki-67 is an antigen present in the nuclei of cells in all phases of the cell cycle as well as in mitosis, but quiescent cells in the G0 phase do not express it. Ki-67 is an excellent marker to determine the growth fraction of a cell population. The fraction of Ki-67 positive tumor cells (the Ki-67 labelling index) is often correlated with the clinical course of cancer. The best-studied examples in this context are carcinomas of the prostate, brain, breast and nephroblastoma (Li et al., 2013).

VEGF is important in carcinogenesis as it is responsible for the growth of the neoplasm and is also involved in the mechanism of metastasis. Angiogenesis is essential for tumor proliferation, progression and the formation of metastasis (Melinocovici et al., 2018).

**MATERIALS AND METHODS**

This retrospective study included 60 cases of endometrial hyperplasia and 60 cases of endometrial carcinoma, total cases 120. Formalin-fixed paraffin-embedded blocks were provided from the Pathology Department, Tanta University. Inclusion criteria included all available cases of endometrial hyperplasia and primary endometrial carcinoma. Cases without a full clinicopathological sheet or bad quality of tissue blocks were excluded. This study was performed during the period from January 2017 to June 2020. All procedures performed in the current study (specifically involving human participants) were accepted from the Local Research Ethics Committee of Faculty of Medicine, Tanta University. Detailed clinicopathologic data of these patients were obtained from their medical reports. FIGO Grading and staging of endometrial carcinoma with subtyping of cases were according to the WHO classification 2014 (Kurman et al., 2014).

**Immunohistochemical staining**

Formalin-fixed paraffin-embedded tissue sections (4-μm) were mounted on to APES-coated glass slides (Chenglin, Shanghai, China). Slides were dewaxed in xylene twice for 10 min and rehydrated through graded ethanol. Antigen retrieval was performed in 0.01 mol/l citrate buffer (pH 6.0) by boiling for 10 min. Endogenous peroxidase activity was suppressed with 3% hydrogen peroxide for 10 min. After washing with phosphate-buffered saline (PBS), the slides were blocked with 5% BSA for 30 min at 37°C. Sections were incubated with primary antibody to

- **OCT-4** antibody was an epitope-specific purified mouse monoclonal antibody raised against the OCT-4 antigen, (CA 95677) (Cell marque, CA, USA). It was received as 7 mL. Ready to use.
- **Ki-67** (Kit no. Cat. #RB-1510-R7 (7.0ml), labvision) (dilution 1:800)
- **VEGF** primary rabbit polyclonal antibody to human (Kit no. Cat. MAS-17041, Labvision), at 4°C overnight in a humidified chamber. After washing three times with PBS, sections were incubated for 30 min with the secondary antibody (peroxidase goat anti-mouse IgG; dilution, 1:300; catalog no. 32230; Zymed, San Diego, CA, USA). After washing three times in PBS, 3,3’-diaminobenzidine (as chromogen) was used. Slides were counter-stained with hematoxylin for 1 min. Sections incubated without the primary antibody were used as negative controls.

**Interpretation of OCT-4 immunostaining**

OCT-4 staining was detected as brownish nuclear staining (Zhou et al., 2011) defined...
immunohistochemical scoring for OCT-4 based on the percentage of immunopositive cells into negative (0 ), no staining in tumor cells; (+1) nuclear staining in more than 10% tumor cells; and (+2 ) nuclear staining in more than 50% tumor cells.

**Ki-67 labelling index**

The sections were examined at low magnifications (X40 and X100) to identify the area with the most intense staining. Only cells with a distinct nuclear Ki-67 staining were considered positive and the percentage of immunoreactive nuclei was calculated and scored as negative (no stained cells), low index (5% to 25%) and high index (more than 25 %) (Masjeed et al., 2017).

**Interpretation of VEGF immunostaining**

VEGF was detected as cytoplasmic brownish staining. Immunostaining score was classified according to the percentage and intensity of staining into negative, weak staining in less than 10% tumor cells. Moderate staining in 11 to 50%, and strong in more than 50% of tumor cells were considered as positive results, according to Guşet et al., 2010.

**Statistical analysis**

Statistical analysis was performed using a statistical package for the social sciences (SPSS version 23, IBM corp., Armonk, New York, USA). Categorical variables were expressed as frequencies and percentages, whereas mean± SD was used to express continuous variables. Chi-square ($\chi^2$) Test was performed for comparing categorical variables. Fisher’s exact test was applied when one of the expected frequencies was up to 5. P values of less than 0.05 were considered statistically significant and those of less than 0.001 were considered highly significant.

**RESULTS**

1. **Clinicopathologic Characteristics**

This study was carried on 120 specimens of endometrial lesions, which were divided into (Group I: 60 cases of endometrial hyperplasia, Group II: 60 cases with endometrial carcinoma. The mean age of endometrial hyperplasia cases was 53.88 ± 12.36 years (range 32-84) and the mean age of endometrial carcinoma cases was 54.77 ± 9.81 years (range 35-81). One hundred cases complained of abnormal vaginal bleeding and discharge. Only two cases of endometrial carcinoma patients were presented with purulent vaginal discharge and a sense of pelvic pressure or discomfort. The remaining cases were found accidentally with other uterine lesions like fibroids.

2. **Histopathological and immunohistochemical**

According to WHO (2014) histopathological classification of endometrial hyperplasia cases were classified into (Kurman et al., 2014). Twenty-four cases of simple endometrial hyperplasia without atypia representing (40%) of endometrial hyperplasia cases, 16 cases of complex endometrial hyperplasia without atypia representing (26.7%) and 20 cases of atypical endometrial hyperplasia representing (33.3%) of endometrial hyperplasia cases.

Endometrial carcinoma cases were classified into 38 cases of endometrioid carcinoma representing (63.3%) of all endometrial carcinoma cases, 10 cases were clear cell endometrial carcinoma (16.7%), 10 cases of papillary serous endometrial carcinoma (16.7%) and 2 cases mucinous endometrial carcinoma (3.3%).

According to the FIGO grading system (2009) of endometrial carcinoma, the included 60 cases were graded as follows: seventeen cases of well-differentiated endometrial carcinoma representing 28.3% of the total number of studied endometrial carcinoma cases, 15 cases (28.3%) were moderately differentiated and 28 cases of poorly differentiated endometrial carcinoma representing 46.7% of the total number of the studied cases of endometrial carcinoma. Regarding myometrial invasion, 5 cases (8.3%) were limited to the endometrium without myometrial invasion. 15 cases (25%) invaded less than half the myometrium and 40 cases (66.7%) invaded more than half the myometrium.

According to FIGO committee (2009) of endometrial carcinoma, the included 60 cases of endometrial carcinoma were staged as follows: Stage IA which included 20 cases (57.1%). Stage IB included 15 cases (42.9 %).
Table 1. The relation between OCT-4 expression and clinicopathologic parameters of endometrial carcinoma

<table>
<thead>
<tr>
<th></th>
<th>OCT - 4</th>
<th>Chi-square</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total N=60</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>Positive N=52 (86.7%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0 N=8 (13.3%)</td>
<td>+1 N=9 (17.3%)</td>
<td>+2 N=43 (82.7%)</td>
</tr>
<tr>
<td></td>
<td>N=38</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>21.1%</td>
<td>78.9%</td>
</tr>
<tr>
<td></td>
<td>Mucinous</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>Papillary</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>Clear</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>Endometrioid</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I N=17</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>47.1%</td>
<td>52.9%</td>
</tr>
<tr>
<td></td>
<td>II N=15</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>III N=28</td>
<td>0</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>Grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I N=35</td>
<td>8</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>22.9%</td>
<td>77.1%</td>
</tr>
<tr>
<td></td>
<td>II N=15</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>III N=9</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>IV N=1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td>Staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No N=5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>40.0%</td>
<td>60.0%</td>
</tr>
<tr>
<td></td>
<td>&lt; 50 N=15</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>13.3%</td>
<td>86.7%</td>
</tr>
<tr>
<td></td>
<td>&gt; 50 N=40</td>
<td>4</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>10.0%</td>
<td>90.0%</td>
</tr>
<tr>
<td></td>
<td>myometrial invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=8</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>40.0%</td>
<td>60.0%</td>
</tr>
<tr>
<td></td>
<td>N=15</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>13.3%</td>
<td>86.7%</td>
</tr>
<tr>
<td></td>
<td>N=40</td>
<td>4</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>10.0%</td>
<td>90.0%</td>
</tr>
</tbody>
</table>

* Significant (P value < 0.05).

Stage II: Fifteen cases representing 25% of endometrial carcinoma cases, included tumors invading cervical stroma, but not extending beyond the uterus. Stage III: Nine cases representing 15% of endometrial carcinoma cases. All of them were of stage IIIA, and they included tumor with invasion of serosa of the corpus. Stage IV: One case of uterine papillary serous carcinoma, representing 1.7% of endometrial carcinoma cases. It was of stage IVA, and they included tumor with invasion of bowel mucosa.

**OCT4**: OCT-4 expression was detected by nuclear staining in only 13 cases (21.7%) of endometrial hyperplasia, all of them were of atypical endometrial hyperplasia and in 86.7% of endometrial carcinoma cases. The statistical analysis showed a significant direct relation between OCT-4 expression and grade of endometrial carcinoma cases, depth of myometrial invasion and stage of endometrial carcinoma cases (Figure 1 and Tables 1,4,5).

**Ki-67**: Low index nuclear Ki-67 expression was detected as nuclear staining in 6 cases (10%) of endometrial hyperplasia, all of them were of atypical endometrial hyperplasia [all of these six cases were low index]. In the case of endometrial carcinoma patients, Ki-67 expression was detected in 90% of endometrial carcinoma cases. There was a statistically significant direct relation between Ki-67 expression and histopathologic types of endometrial carcinoma cases, grading and stages were statistically significant (Figure 2 and Tables 2,4,5).

**VEGF**: VEGF expression was detected in 83.3% of endometrial carcinoma cases, while only 8 cases of endometrial hyperplasia cases showed
positive expression. The relation between VEGF and histopathologic types, grade, myometrial invasion and stages of endometrial carcinoma cases was statistically significant as in Table 3. As high expression of VEGF was associated with higher grade stages of endometrial carcinoma and myometrial invasion (Figure 3 and Tables 3,4,5).

**Correlation between different immunomarkers expression in atypical endometrial hyperplasia versus grade 1 endometrial carcinoma cases:** Among the studied markers, only Ki-67 showed a statistically significant relation between atypical endometrial hyperplasia and grade I endometrial carcinoma cases (P value=0.005). It was positive in (76.5%) of grade 1 endometrial carcinoma cases and (30%) of atypical endometrial hyperplasia cases (Table 5).

**DISCUSSION**

The present study included 120 selected cases of endometrial lesions classified histologically into two major groups, group I constituted of 60 cases of endometrial hyperplasia, and group II constituted of 60 cases of endometrial carcinoma. The present work aimed to study the relationship between OCT-4, Ki-67 and VEGF immunohistochemical expression and clinicopathologic data of endometrial hyperplasia and carcinoma.

OCT-4 is a transcription factor that forms a core regulatory network that determines endometrial cancer stem cells (ESC) self-renewal and differentiation. These ESC-associated proteins may also contribute to tumorigenesis. OCT-4 expression was positive in (86.7%) of endometrial carcinoma cases, with
Table 3. The relation between VEGF and clinicopathologic parameters of endometrial carcinoma.

<table>
<thead>
<tr>
<th></th>
<th>VEGF</th>
<th>Chi-square</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total N=60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=10 (16.7%)</td>
<td>N=50 (83.3%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid</td>
<td>N=38</td>
<td>28</td>
<td>15</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>26.3%</td>
<td>73.7%</td>
<td>53.6%</td>
<td>46.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td>N=2</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>50.0%</td>
<td>50.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td>N=10</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>.0%</td>
<td>100.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clear</td>
<td>N=10</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>.0%</td>
<td>100.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N x 10</td>
<td>P-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>histological type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid</td>
<td></td>
<td>23.983</td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clear</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>grade</td>
<td></td>
<td>36.442</td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>N=17</td>
<td>10</td>
<td>7</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>58.8%</td>
<td>41.2%</td>
<td>71.4%</td>
<td>28.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>N=15</td>
<td>0</td>
<td>15</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>40.0%</td>
<td>60.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>N=28</td>
<td>0</td>
<td>28</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>17.9%</td>
<td>82.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stage</td>
<td></td>
<td>27.253</td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>N=35</td>
<td>10</td>
<td>25</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>28.6%</td>
<td>71.4%</td>
<td>60.0%</td>
<td>40.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>N=15</td>
<td>0</td>
<td>15</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>6.7%</td>
<td>93.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>N=9</td>
<td>0</td>
<td>9</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>0.0%</td>
<td>100.0%</td>
<td>.0%</td>
<td>100.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>N=1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myometrial invasion</td>
<td></td>
<td>16.102</td>
<td>0.003*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>N=5</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>40.0%</td>
<td>60.0%</td>
<td>33.3%</td>
<td>66.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50</td>
<td>N=15</td>
<td>3</td>
<td>12</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>20.0%</td>
<td>80.0%</td>
<td>75.0%</td>
<td>25.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 50</td>
<td>N=40</td>
<td>5</td>
<td>35</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% 100.0%</td>
<td>12.5%</td>
<td>87.5%</td>
<td>17.1%</td>
<td>82.9%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Significant (P value<0.05).

significant direct relation with the histopathological types, as it was positive in (78.9%) of endometrioid carcinoma cases while positive in all cases of mucinous, papillary serous and clear types with the highest expression (score +2) in all cases of papillary serous, clear types and 73.3% and 50% of positive cases of endometrioid and mucinous carcinoma types. However, Shorky et al., (2017) reported that OCT-4 expression in their study was positive in all cases of endometrial carcinoma with the highest expression in (37%) of cases of type 1 carcinoma, whereas type 2 showed low expression. These discrepancies can probably be explained by the variations in methodology, principally differences in the specificity of antibody and dilution used.

In a present study, the highest expression of OCT-4 was positive in (100%) of grade 3 endometrial carcinoma [Which included poorly differentiated endometrioid carcinoma, papillary serous and clear cell type] with the highest expression (score +2) in (96.4%) of cases of grade 3. Also, in grade 2 endometrial carcinoma cases, it was positive (100%), while it was only 52.9% in grade 1 endometrial carcinoma. It was found that there was a significant direct relation between OCT-4 immunohistochemical expression and grading of endometrial carcinoma cases; as higher expression of OCT-4 was related to higher tumor grade.

These findings were parallel to those of Xie et al. (2019) who found a significant direct relation between OCT-4 expression and FIGO grading of endometrial carcinoma in their series as OCT-4 expression was positive in all cases of grade 3 and grade 2 endometrial carcinoma, while it
Table 4. Correlation of immunohistochemical results between the two studied groups (Endometrial hyperplasia and Endometrial carcinoma).

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>-ve</th>
<th>+ve</th>
<th>X²</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCT-4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>60</td>
<td>47 (78.3%)</td>
<td>13 (21.7%)</td>
<td>51.052</td>
<td>0.001*</td>
</tr>
<tr>
<td>Endometrial carcinoma</td>
<td>60</td>
<td>8 (13.3%)</td>
<td>52 (86.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>60</td>
<td>54 (90%)</td>
<td>6 (10%)</td>
<td>76.801</td>
<td>0.001*</td>
</tr>
<tr>
<td>Endometrial carcinoma</td>
<td>60</td>
<td>6 (10%)</td>
<td>54 (90%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>60</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td>58.871</td>
<td>0.001*</td>
</tr>
<tr>
<td>Endometrial carcinoma</td>
<td>60</td>
<td>10 (16.7%)</td>
<td>50 (83.3%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Significant (P value < 0.05).

Table 5. Correlation of immunohistochemical results between atypical endometrial hyperplasia versus grade 1 endometrial carcinoma cases.

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>-ve</th>
<th>+ve</th>
<th>X²</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCT-4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atypical endometrial hyperplasia</td>
<td>20</td>
<td>7 (35%)</td>
<td>13 (65%)</td>
<td>0.552</td>
<td>0.457</td>
</tr>
<tr>
<td>Grade 1 endometrial carcinoma</td>
<td>17</td>
<td>8 (47.1%)</td>
<td>9 (52.9%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atypical endometrial hyperplasia</td>
<td>20</td>
<td>14 (70%)</td>
<td>6 (30%)</td>
<td>7.942</td>
<td>0.005*</td>
</tr>
<tr>
<td>Grade 1 endometrial carcinoma</td>
<td>17</td>
<td>4 (23.5%)</td>
<td>13 (76.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atypical endometrial hyperplasia</td>
<td>20</td>
<td>12 (60%)</td>
<td>8 (40%)</td>
<td>0.012</td>
<td>0.942</td>
</tr>
<tr>
<td>Grade 1 endometrial carcinoma</td>
<td>17</td>
<td>10 (58.8%)</td>
<td>7 (41.2%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Significant (P value < 0.05).

Figure 1. OCT4 Immunohistochemical expression  
A: case of complex endometrial hyperplasia showing score (0) nuclear expression of OCT-4 (X 400).  
B: Conventional endometrioid carcinoma (grade 2) showing score (+1) nuclear expression of OCT-4 (X 400).  
C: Conventional endometrioid carcinoma (grade 3), showing score (+2) nuclear expression of OCT-4 (X 400).  
D: A case of uterine papillary serous type, showing score (+2) nuclear expression of OCT-4 (X 200).
Figure 2. KI-67 Immunohistochemical expression  A: a case of atypical endometrial hyperplasia showing low index nuclear expression of KI-67 (X 400). B: Conventional endometrioid carcinoma (grade 1), showing a high index nuclear expression of KI-67 (X 400).

Figure 3. VEGF Immunohistochemical expression  A: A case of atypical endometrial hyperplasia showing strong cytoplasmic expression for VEGF (X 400). B: A case of conventional endometrioid carcinoma (grade 3), showing strong VEGF expression (X 400).

was only 50% in grade 1 endometrial carcinoma. On the other hand, Pityński et al. (2015) reported non-significant relation between OCT-4 expressions and grade 1 and 2 endometrial carcinomas compared to grade 3 carcinomas.

OCT-4 was positive in 60% of cases that did not show myometrial invasion, 86.7% of cases with invasion less than half the myometrium, and 90% of cases with invasion more than half the myometrial invasion. Although the relation between OCT4 and depth invasion did not reach a statistically significant relation, OCT4 was found to increase with the level of myometrial invasion, as it was positive in (90%) of cases with myometrial invasion >50%.

OCT-4 was expressed in 77.1% of endometrial carcinoma stage I cases, and 100% positive in stages II, III and stage IV cases. The relation between OCT-4 immunohistochemical expression and stage of endometrial carcinoma reached significant value with a direct relationship. These results indicate that elevated expression of OCT-4 is positively associated with late-stage progression and worse prognosis of endometrial cancer patients. Xie et al. (2019) reported that OCT-4 is an important transcription factor that contributes to both tumor metastasis and chemoresistance. Kutilin et al. (2019) also, has been reported that poorly differentiated tumors exhibit highly activated embryonic stem cell signals with accumulating evidence that the activation of key transcription factors like OCT4 is important for tumor oncogenesis, progression and metastasis.

OCT4 was positive in only 13 cases (21.7%) of endometrial hyperplasia, all of them were of atypical endometrial hyperplasia and in (86.7%) of endometrial carcinoma cases. There was a significant difference between expression of OCT4 in endometrial hyperplasia and endometrial carcinoma cases but no significant difference could be found between atypical hyperplasia and carcinoma. Although the expression of OCT 4 might be an indicator for the progression of endometrial hyperplasia to carcinoma it could not be used as a diagnostic tool to differentiate between atypical endometrial hyperplasia and carcinoma.
Shorky et al. (2017) reported the expression of OCT4 in nine cases (30%) of endometrial hyperplasia cases out of total of 30 cases: two (22.2%), four (44.4%), and three (33.3%) cases of simple endometrial hyperplasia, atypical endometrial hyperplasia and complex endometrial hyperplasia, respectively. This discrepancy in results to our study could be attributed to a small number of cases in their study.

Ki-67 is a cellular marker for proliferation and it is an excellent marker to determine the growth fraction of a given cell population (Rossi et al., 2020). Regarding endometrial carcinoma cases, Ki-67 expression was positive in 90 %. It was found that there was a significant relation between Ki-67 expression and the histopathologic types of studied cases of endometrial carcinoma. It was positive in 84.2% of endometrioid carcinoma cases and positive in all cases (100%) of mucinous type, papillary serous type and clear cell type of endometrial carcinoma with a high labelling index. There was a difference between the present study & the results of Yu et al. (2015) regarding Ki-67 percentage as it was positive in (64.2%) of endometrial carcinoma cases, may be due to the absence of aggressive types (uterine papillary serous carcinoma and clear cell carcinoma) in their study, which were completely positive for Ki-67 in our study.

In the present study, there was a significant direct relation between Ki-67 expression and stage of endometrial carcinoma cases, as Ki-67 positive expression was lowest in grade 1 (76.5%), while it represented 93.3% and 96.4% in grade 2 & grade 3 cases respectively with high labelling index in 77.8% and 42.9% of grades 3 and 2, respectively.

A progressive increase of Ki-67 in grade 3 may be linked to tumor aggressiveness and loss of differentiation of endometrial cancer. This was in coincidence with the results of Gülseren et al., (2020). On the other hand, Yang et al., (2016), found an insignificant direct relation between the grade of endometrial carcinoma cases and Ki-67 expression in their studied cases.

In relation to the depth of myometrial invasion, Ki-67 was positive in 80% of cases without myometrial invasion, 93.3% of cases with invasion less than half of the myometrium and 90% of cases with invasion more than half of the myometrium. Although the relation between Ki-67 and depth of myometrial invasion did not reach a statistical significance Ki-67 was found to be significantly related to stage.

As dealing with the staging of endometrial carcinoma cases, the present study proved that there was a significant direct relation between Ki-67 expression and stage as Ki-67 expression was positive in 100% of stage IV cases and stage II cases, 93.3% of stage II cases and 85.7 % of stage I cases. So, those cancers with the greatest cell proliferation had the poorest clinical outcome and are more likely to be associated with disease metastasis and recurrence. This was in agreement with the findings of Furau et al., (2019), who found also a positive relation between Ki-67 expression on one hand with stage and depth of myometrial invasion.

In the present study, 6 out of 60 cases of endometrial hyperplasia were positive for Ki-67 immunoreactivity, representing 10% (all of these six cases were atypical hyperplasia with low labelling index). This can be explained by the increase in the malignant potential of atypical endometrial hyperplasia cases. This is in agreement with the findings of Zimik et al. (2020) who did not find expression of Ki-67 in nearly all their studied cases of endometrial hyperplasia without atypia.

Ki-67 expression in endometrial carcinoma cases (90%) was significantly higher than that of endometrial hyperplasia cases (10%). Also, there was a significantly higher Ki-67 expression in grade1 endometrial carcinoma cases (76.5%) than that of atypical endometrial hyperplasia cases (30%). This finding was in coincidence with that of Shalini et al., (2019) who found that there was a significant positive relationship between Ki-67 expression in endometrial hyperplasia and endometrial carcinoma. So, the Ki-67 labelling index could be used in differentiation between endometrial hyperplasia with atypia and grade 1 endometrial carcinoma. Further studies on a larger number of cases are needed to reach a cut-off value for Ki 67 in the diagnosis of...
endometrial carcinoma and differentiation between atypical endometrial hyperplasia and grade 1 endometrial carcinoma.

Both tumor cell proliferation (Ki-67) and angiogenesis seem to be important for the development of aggressive tumors and to carry an independent significance for the tumor growth potential. Hence, the present research attempted to examine the expression of VEGF in endometrial hyperplasia and endometrial carcinoma, to characterize its relationship with a set of clinicopathologic characteristics.

Most of the endometrial carcinoma cases (83.3%) showed VEGF positive expression, with significant relation with histopathological types of endometrial carcinoma cases. VEGF expression was highest in grade 2 and grade 3 endometrial carcinoma (100%) and decreased expression in grade 1 (41.2%) cases. It was found that there was a significant direct relation between VEGF expression and grade of endometrial carcinoma. This was in agreement with the results of Wang et al. (2014).

Strong positivity for VEGF in grade 2 and grade 3 carcinoma could be explained that VEGF plays a role in tumor progression. This was in coincidence with Zinovkin et al. (2019), who found low VEGF expression in well-differentiated endometrial carcinoma cases in comparison to poorly differentiated cases.

VEGF had a significant relationship with a depth of myometrial invasion, as it was positive in 87.5% of cases with an invasion with more than half the myometrium, 80% of cases that show invasion less than half of the myometrial, and 60% of cases without myometrial invasion. As regards the stage of endometrial carcinoma, VEGF was expressed in all cases of stage IV, stage III and stage II (100%), while it was found in (71.4%) of stage I tumours with significant relation with the stage. This finding was in coincidence with Sunita et al. (2018) who reported that VEGF expression occurred more often in endometrial cancers with deep myometrial invasion.

These results emphasize the role of VEGF in carcinogenesis as it is a potent pro-angiogenic factor and also a key mediator of neovascularization, a process that is mandatory in the pathogenesis of malignant tumors. Its overexpression in tumor cells stimulates tumor growth and metastasis in cancer (Guşet et al., 2010; Sunita et al., 2018).

In the present study 52 out of 60 cases of endometrial hyperplasia didn’t show positivity for VEGF, while only 8 cases of atypical endometrial hyperplasia were positive for VEGF with a strong expression representing (13.3%) of cases. There was a significant higher VEGF expression in endometrial carcinoma cases (83.3%) than that of endometrial hyperplasia cases (13.3%). This finding was in coincidence with that of Hassan and Ibrahim, (2020) who found that there is a higher expression of VEGF in endometrial carcinoma to hyperplasia with a significant relationship. But, there was weak cytoplasmic positive staining in atypical endometrial hyperplasia while in benign endometrial hyperplasia, the expression was negative.

These results emphasize that high expression of VEGF seems to have a role in the progression of endometrial hyperplasia into endometrial carcinoma. However, as regards the relation of VEGF expression in atypical endometrial hyperplasia versus grade 1 endometrial carcinoma; it was insignificant which explain that VEGF could not be used as a diagnostic tool in differentiation between them.

CONCLUSION
OCT-4, Ki-67 and VEGF expression showed a positive correlation with tumor aggressive pathological parameters. The Ki-67 labelling index can be used in differentiation between endometrial hyperplasia with atypia and grade 1 endometrial carcinoma. Although OCT-4 and VEGF expressed in endometrial cancer more than hyperplasia, they could not be used as diagnostic tools to differentiate between atypical endometrial hyperplasia and carcinoma. However, it indicates that they have a role in malignant transformation.

CONFLICTS OF INTEREST
All authors have approved this article and declare no conflicts of interest.

FUND
No fund was received for this work.
References


Egyptian Association for Cancer Research (EACR)  
http://eacr.tanta.edu.eg/

EACR is an NGO society that was declared by the Ministry of Social Solidarity (Egypt) No. 1938 in 19/11/2014 based on the initiative of Prof. Mohamed Labib Salem, the current Chairman of EACR. EACR aims primarily to assist researchers, in particular young researchers in the field of cancer research through workshops, seminars and conferences. Its first international annual conference entitled "Anti-Cancer Drug Discovery" was successfully organized in April 2019 (http://acdd.tanta.edu.eg). Additionally, EACR aims to raise the awareness of the society about the importance of scientific research in the field of cancer research in prediction, early diagnosis and treatment of cancer. EACR is also keen to outreach the scientific community with periodicals and news on cancer research including peer-reviewed scientific journals for the publication of cutting-edge research. The official scientific journal of EACR is "International Journal of Cancer and biomedical Research (IJCBR: https://jcb.journals.ekb.eg) was successfully issued in 2017 and has been sponsored by the Egyptian Knowledge Bank (EKB: www.ekb.eg).

EACR Chairman,  
Prof. Mohamed Labib Salem, PhD  
Professor of Immunology  
Faculty of Science, Tanta University, Egypt
ABOUT JOURNAL

International Journal of Cancer and Biomedical Research (IJCBR), a publication of the Egyptian Association for Cancer Research (EACR), is a peer-reviewed online journal published quarterly. The journal allows free access (Open Access) to its contents and permits authors to self-archive a final accepted version of the articles on any OAI-compliant institutional / subject-based repository.

Aim And Scope

Aim: The main aim of IJCBR is to attract the best research in animal and human biology in health and diseases from across the spectrum of the biomedical sciences at the molecular, cellular, organ, and whole animal levels especially those that are related to cancer research, including causes, prediction, diagnosis, prognosis and therapy.

Scope: It is essential reading for all researchers interested in biochemistry, cancer, microbiology, nutrition, physiology, genetics, immunology, epidemiology, medical economics, human biology, bioinformatics, biotechnology, nanotechnology, and disease modeling.

Publication Ethics

Researchers should conduct their research from research proposal to publication in line with the best practices and codes of conduct of relevant professional bodies and/or national and international regulatory bodies. IJCBR accepts manuscripts prepared in accordance with the “Uniform Requirements for Submission of Manuscripts for Biomedical Journals adopted by the International Committee of Medical Journal Editors (ICMJE) and the Committee on Publication Ethics (COPE). Details of ICMJE and COPE are available at http://www.icmje.org/ and http://publicationethics.org/

Peer Review Process

After the IJCBR editor receives a manuscript, the first step is to confirm that the manuscript meets the journal’s rules for content and format, including similarity check (plagiarism) which should be less than 25%. If the manuscript meets the journal’s rules, the editor then assign it to the double-blind peer review process. The IJCBR editor send the manuscript to at least two experts in the field for RIGOROUS scientific evaluation. The experts – called peer reviewers – will then prepare a report that assesses the manuscript and return it to the editor through the IJCBR portal. Upon the first submission, this reviewing process takes about 4 to 6 weeks. After reading the peer reviewer’s report, the editor will decide one of the following four options:

1. Reject the manuscript.
2. Accept the manuscript
3. Ask the authors to revise and resubmit the manuscript after responding to the peer reviewers’ feedback.
4. Ask for peer-review from additional reviewers.

If the authors resubmit the manuscript, the IJCBR editor will ask the same peer-reviewers to look over the manuscript again to confirm that their concerns have been addressed. This is called re-review process. This second revision (if applicable) takes about another 4 to 6 weeks. At this point, the abstract of the article appears in press. The online publication (the PDF format) of the final version of the manuscript takes from 2 to 4 weeks. As such, the total publication cycle takes from 2 to 4 months. This cycle can be reduced to 4 to 6 weeks (fast track publication) for the manuscripts with outstanding findings.

The peer-review process used by IJCBR includes comments on errors in the study’s methods or analysis that raise questions about the findings, or sections that need clearer explanations. The peer-review process also includes the importance and novelty of the manuscript and its interest to the journal’s audience. The IJCBR uses double-blind review, which means that both the reviewers and authors identities are concealed from the reviewers, and vice versa, throughout the review process. To facilitate this, authors need to submit a Title Page containing the Authors details and Blinded Manuscript with no author details as 2 separate files.
Publisher

The International Journal of Cancer and Biomedical Research (IJCBR) is an International and interdisciplinary journal of preclinical and clinical studies in the area of cancer and biomedical research. It is a peer-reviewed journal in English, published quarterly (in March, June, September, and December) by the Egyptian Association for Cancer Research (EACR) in both print and online formats (4 issues making a volume). Special issues or supplements may also be produced from time to time upon agreement with the Editorial Board.

Scope

The main aim of IJCBR is to attract the best research in animal and human biology in health and diseases from across the spectrum of the biomedical sciences at the molecular, cellular, organ, and whole animal levels especially those that are related to cancer research, including causes, prediction, diagnosis, prognosis and therapy.

Publication Fees

The journal does charge for submission, processing or publication of manuscripts (2000 LE for Egyptians or $300 for non-Egyptians; EACR members receive 15% discount on publication). Of them Peer-review fees (300 LE) should be paid on submission (non-refundable). For the fast track production of the accepted manuscript, another 500 LE is paid.

General specifications for different types of article

- Submitted manuscripts should not have been published previously, except in a limited form (e.g. short communication to a symposium or as part of MSc or PhD theses) and should not be under consideration for publication by other journals.
- All co-authors should agree with the content of the manuscript. Authors must have obtained permission to use any copyrighted material in the manuscript before submission.

IJCBR publishes different types of articles

- **Original Article (6000 words with 4 tables and 4 figures, maximum 8 display items):** Articles with novel findings are the target of IJCBR. Articles presenting a detailed description of a new technique, comparison of existing methods, meta-analyses with comprehensive and in-depth discussion are considered. Papers in a numbered series are not accepted unless all are submitted at the same time.
- **Short communications or case study (3000 words with 4 display items):** Short communications present exceptionally exciting, novel or timely contents are considered. They will be peer-reviewed in the same way as research papers. The references are restricted to 15.
- **Reviews or systematic review (9000 words with 10 display items):** They are invited by the Editorial Board or unsolicited. Review articles have to be contemporary and comprehensive and add information to the knowledge. Sharp critical analyses of novel data or concepts are encouraged. When relevant, a statistical analysis of data and a meta-analysis approach are recommended.
- **Opinion papers, letter to the editor or comment to the editor (1500 words with 2 display items):** They are submitted by invitation of the Editorial Board. They are short papers, which aim to inform scientists, industry, and the public and policymakers about cutting-edge issues in research or the impact of research. They reflect the opinion of their authors who bear full responsibility of the published paper. The references are restricted to 10.
- **Conference/Symposium papers:** The journal will consider for publication the results of original work and critical reviews that are presented at conferences/symposia. Symposium organizers who wish to publish bundles of papers from a symposium/conference in IJCBR should first contact the Editor-in-Chief of the IJCBR (EACR@univ.tanta.edu.eg) for agreement. Supplementary material can be proposed and will be made available online. The responsibility for the preparation of a paper in a form suitable for publication lies with the author.
- **Thesis:** IJCBR can publish the summary and abstract of Master and PhD theses in a special issue.
**English:** Good quality of written English is required. Spelling may be in British or American English but must be consistent throughout the paper. Care should be exercised in the use of biological terminology that is ill-defined or of local familiarity only. We recommend that authors have their manuscripts checked by an English language native speaker before submission.

**Manuscript layout:** Manuscripts should be prepared using a standard word processing program and presented in a clear readable format with easily identified sections and headings. The manuscript layout is based on the following directions.

- The main text contains Title, Abstract, Keywords, Introduction, Material and Methods, Results, Discussion, References, Tables, figures.
- The title needs to be concise and informative. Use bold, with an initial capital for the first word only and for words that ordinarily take capitals
- Short (running) title (max 80 characters including spacing).
- The article text should be typed with double-line spacing with wide margins (2.5 cm).
- The lines must be continuously numbered; the pages must also be numbered.
- Font Calibri 12 should be used for the text, and 12 for the tables, figure legends and references.
- The sections should typically be assembled in the following order:
  - Title page contains title, authors' names, full affiliations, acknowledgements and the corresponding author’s contacts and Short title.

**Abstract (max 250 words, single paragraph):** The abstract should be complete and understandable without citation, references, table or figure. Use structured abstract: Background, Aim, Materials & Methods, Results and Conclusion. The context and the rationale of the study are presented succinctly to support the objectives. The experimental methods and main results are summarized but should not be overburdened by numerical values or probability values. The abstract ends with a short and clear conclusion.

**Keywords:** Up to five short and specific keywords should complement the title with respect to indicating the subject of the paper in alphabetic order.

**Introduction:** The introduction briefly outlines the context of the work, presents the current issues that the authors are addressing and the rationale to support the objectives, and clearly defines the objectives.

**Material and methods:** Material and methods should be described in sufficient details so that others can repeat the experiment. Reference to previously published work may be used to give methodological details, provided that said publications are readily accessible and in English. The code of ethics should be followed for all experiments use animals or human samples.

**Statistical analysis of results:** The statistical design and the models of statistical analysis must be described, as well as each of the statistical methods used. Sufficient statistical details must be given to allow replication of the statistical analysis. The experimental unit should be defined (e.g. individual or group of animals).

**Results:** Data are presented as tables and figures. Brief description of the results for each table and figure should be presented. Unpublished data can be mentioned when necessary.

**Discussion:** Should be separate from the Results section and should focus only on intra- and inter-data discussion (the data in the results section) as well as with the relative data in the literature. Don’t repeat information already presented in the Introduction section. Start the first paragraph in the Discussion with a paragraph stating the rationale behind the study, the objectives and the main findings. End Discussion with a short conclusion.

**Acknowledgements:** In this section, the authors may acknowledge (briefly) their support staff.

**Conflict of interest:** All papers with a potential conflict of interest must include a description/explanation in a separate heading.

**Funding details:** The authors should state the source of findings of the study (with research funder and/or grant number). If no fund, the authors should state that the study is self-funded.
References

**Citation of references:** In the text, references should be cited by the author(s) surname(s) and the year of publication (e.g. Salem, 2020). References with two authors should be cited with both surnames (e.g. Salem and Meshrif, 2021). References with three or more authors should be cited with the first author followed by et al. (in italics; e.g. Salem et al., 2021). Names of organizations used as authors (e.g. Food and Drug Administration) should be written out in full in the list of references and on the first mention in the text. Subsequent mentions may be abbreviated (e.g. FDA).

- List of references. Literature cited should be listed in alphabetical order by authors’ names. It is the author’s responsibility to ensure that all references are correct. All authors should be written and so the full journal name.
- References from journal articles are formatted in APA as this example: Al-Amoudi WM (2018). Toxic effects of Lambda-cyhalothrin on the rat thyroid. Involvement of oxidative stress and ameliorative effect of ginger extract. Toxicology Reports, 5: 728-736.
- References from books or official reports are formatted as this example. Kebreab E, Dijkstra ANM, Bannink A, Gerrits WJJ, & France J (2006). Nutrient digestion and utilization in farm animals. CABI Publishing. Wallingford, UK.

Tables:
The data should be presented in tables or in graphs, not both.
- Each table should be placed on a separate page at the end of the main text.
- Tables are numbered consecutively using Arabic numbering. They are referred to as Table 1, Table 2, etc., with capital 'T', no italics.
- Each table has its explanatory caption. The caption is sufficient to permit the table to be understood without reference to the text.
- Abbreviations used in tables/figures have to be defined either as footnotes or in the caption.

Figures
- Package the figures in a single PowerPoint file. Each figure in a separate slide.
- Figure size should be readable in a width of approximately 8-175 mm (i.e. the maximum size of printing over two columns).
- Ensure that the font size is large enough to be readable at the final print size, use Calibri font to ensure that they are consistent throughout the figures.
- The figures should preferably be provided as TIFF or EPS files.
- The resolutions of figures must be at least 300 dpi.
- Preparation of images for a manuscript: For guidance, we refer to the Journal of Cell Biology’s instructions to authors (http://jcb.rupress.org/site/misc/ifora.xhtml#image_aquisition).
- If a cropped image is included in the main text of a paper (e.g. a few lanes of a gel), display the full original image, including the appropriate controls, the molecular size ladder and/or the scale as relevant, as a single figure in a Supplementary Material file to facilitate peer-review and for subsequent online publication.
- Supplementary material is submitted along with the main manuscript in a separate file and identified at uploading as “Supplementary File – for Online Publication Only” The title of the article is included at the top of the supplementary material.

**Corresponding author’s guidelines:** Upon acceptance the corresponding author is required to send his/her recent formal photo to be attached to the front page of the article.
Editor-in-Chief

Mohamed Labib Salem, PhD
Tanta University, Egypt

Managing Editor

Wesam Meshref, PhD
Tanta University, Egypt
Sohaila Galal, PhD
Tanta University, Egypt

Production and Contact

Hamdi Kandi
Tanta University, Egypt
Email: ijcb100@gmail.com

Advisory Board

Alberto Montero, MD
Taussig Cancer Center, Cleveland, USA

Yi Zhang, MD
Zhengzhou University, China

Mark Robunstein, Ph D
Medical University of South Carolina, USA

Mohsen Farid, Ph D
Derby University, USA

Natarajan Muthusamy, Ph D
Ohio State University, USA

Hideki Kasuya, MD
Nagoya University, Japan

Sherif El-Khamsy, Ph D
Sheffield University, UK

Mohamed Ghamen, Ph D
Kaf Elshikh University, Egypt

Sayed Bakry, Ph D
Alazhar University, Egypt

Sameh Ali, Ph D
Nahala Shoukry

Samira Ghebre, Ph D
National Research Center, Egypt

Nabil Mohy Eldin, PhD
Kafrelsheikh University, Egypt

Nadia Hamdy, Pharm D
Ain Shams University, Egypt

Clinical studies

Hesham Tawfik, MD
Tanta University, Egypt

Mohamed Attia, MD
Tanta University, Egypt

Mohamed Eshanchory, MD
Tanta University, Egypt

Essam Elshiek, MD
Tanta Cancer Center, Egypt

Rasha Eraky, MD
Tanta University, Egypt

Shaima Abou-Kjatwa, MD
Tanta University, Egypt

Marcela Diaz, MD
Cleveland Clinic Foundation, USA

Mohamed Abou El-Enein, MD
Charite Universitatsmedizin Berlin, Germany

Alaa Eldin Almostafa, MD
McGill University, Canada

Olfat Gadallah, MD
Tanta University, Egypt

Nagla Sarhan, MD
Tanta University, Egypt

Nagla Fathy, Pharm D
Zagazik University, Egypt

Mohamed Salama, MD
Mansoura University, Egypt

Monia Marie, MD
Alexandria University, Egypt

Preclinical studies

Mostafa El-Sheikh
Tanta University, Egypt

El-Refaei Kenawy, Ph D
Tanta University, Egypt

Mohamed Noureldin, Ph D
Banaha University, Egypt

Yousry Albolkiny, Ph D
Tanta University, Egypt

Elayed Salim, Ph D
Tanta University, Egypt

Shengdian Wang, Ph D
Chinese Academy of Sciences, China

Sabry El Naggar, Ph D
Tanta University, Egypt

Faris Alenzi, Ph D
Prince Sattam bin Abdulaziz University, KSA

Ibrahim El-Sayed, Ph D
Menoufa University, Egypt

Tarek Aboofadil, Ph D
Assiut University, Egypt

Rabab Kaurar, Ph D
National Research Center, Giza, Egypt

Wael Lofti, Ph D
Alexandria University, Egypt

Asfahr Tabli, Ph D
National Research Center, Egypt

Nahla Shoqry, Ph D
Suez University, Egypt

Medhat Eldenary, Ph D
Tanta University, Egypt

Azza Hasan, Ph D
Menoufa University, Egypt

Nanees Gamal Eldin, Ph D
Tanta University, Egypt

Mohamed Mansour, UK

Sabbah Hammoury, Ph D
Alexandria Ayadi Almoastaqbal Oncology Hospital, Egypt

Nehal Aboufotof, Ph D
Zewail City for Science and Technology, Cairo, Egypt

Amir Elkhani, Ph D
Galaste, San Francisco, USA

Ahmed Alzohairy, Ph D
Zagaz University, Egypt

Wgady Khall, Ph D
National Research Center, Egypt

Amr Amin, Ph D
United Arab Emirates University, UAE

AbdelRahman Zekri, Ph D
National Cancer Institute, Egypt

Hussein Khamis, Ph D
Alexandria University, Egypt

Magdy Mahfouz, Ph D
Kaf Elshikh University, Egypt

Ehab Elbedeweey, Ph D
Tanta University, Egypt

Abeer Badr, Ph D
Cairo University, Egypt

Mamdooh Ghoneum, Ph D
Charles Drew University of Medicine & Science, USA

Haim Abou Elela, Ph D
National Institute of Oceanography and Fisheries, Egypt

Maha El-Demellawi, Ph D
City for Scientific Research & Technology Applications, Egypt

Dessouki Abd-El-Haleem, Ph D
City for Scientific Research & Technology Applications, Egypt